Table 1 Summary of clinicopathological features of the responders and non-responders on the UPCI 08-013 trial

From: Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients

	No. of patients	Gender	Mean age	Tumor site	HPV status
Responders	10	Male: 6	60	OC: 8	HPV+: 1
		Female: 4		OP: 2	HPV-: 9
Non-responders	19	Male: 14	59	OC: 8	HPV+: 9
		Female: 5		OP: 9	HPV-: 10
				L: 2

Back to article page